Apricus Biosciences Inc. is halting development of fispemifene after the selective estrogen receptor modulator (SERM) failed to achieve statistical significance in the primary endpoint of erectile function or the secondary endpoint of low libido in a phase IIb proof-of-concept study in men with secondary hypogonadism (HG) and sexual dysfunction.